European Archives - Page 320 of 1167 - European Medical Journal

Women in Europe Are Receiving More Cycles of IVF: ESHRE 2024

Uptake of in vitro fertilisation and intrauterine insemination has increased among women in Europe, according to data presented at the ESHRE 40th annual meeting.

Socioeconomic Status Affects Fertility Treatment Outcomes: ESHRE 2024

New research presented at ESHRE highlights significant social disparities in achieving live births following assisted reproductive technology treatment.

Plants for Joints Trial: Breaking News from EULAR 2024

Results presented at EULAR 2024, show reductions in DAS28 scores among rheumatoid arthritis patients following a plant-based, whole-food diet, exercise, and stress management regime.

Phase III IMROZ Study of Isa-VRd in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Watch Thierry Facon highlight the Phase III IMROZ study: a global, randomised, Phase III, open-label study evaluating the efficacy and…

EASL 2024 Interview: Sven Francque

During my studies, I was most fascinated by the mechanisms behind diseases. That was what always triggered my interest, as well as trying…

EULAR 2024 Interview: Jette Primdahl

I started my career as a nurse, working for many years in cardiology, a speciality that I really liked. After further education, and…

Spotlight: June 2024

Discover June’s top pharma news in our monthly round-up. From the latest market predictions to new vaccine development initiatives, there’s plenty to discover.

GLP-1 treatments may lower cancer risk in type 2 diabetes patients

A new study finds that patients with type 2 diabetes taking GLP-1 treatments have a reduced chance of developing obesity-related cancers.

EULAR Breaking News: Interferon Signature in Paediatric Sjögren’s Diagnosis

Researchers presented novel findings on the potential utility of the blood interferon signature in diagnosing and stratifying paediatric Sjögren’s disease.

Gestational Carriers Face Higher Health Risks: ESHRE 2024

Research presented at ESHRE 2024 reveals higher risks of severe maternal morbidity and adverse pregnancy outcomes for gestational carriers compared to natural and IVF conceptions.